• Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • FinTech
    • Gadgets & Electronics
    • Health & Bio
    • IoT
    • Marketplaces & E-commerce
    • Robotics
    • Transportation & Logistics
    • Investments
    • Ecosystem & Lists
  • Interviews
  • Events
    • ComeUp
    • NextRise
  • Governments
    • KISA
    • KISED
    • KOCCA
    • KOTRA
    • KTO
    • MSS
    • NIPA
    • SBA
    • SFL
  • Programs
    • SGSC Global Bootcamp 2021
    • LAUNCHPAD
    • COMEUP STARS 120
    • K-Startup Grand Challenge
    • TIPS X beSUCCESS Global Project
    • SFL Global Program
    • KTO Global Showcase
  • Investment Opportunities
    • SGSC Demo Day
    • Launchpad France Demoday
    • TIPS Global Demoday
    • Launchpad USA Demoday
    • Launchpad Indonesia Demoday
  • Submit an Article
  • register
  • login
KoreaTechDesk
No Result
View All Result
KoreaTechDesk
No Result
View All Result
Home Programs K-Startup Grand Challenge

Regulaxis SAS: A French startup that develops regenerative solutions based on new synthetic peptides

James Jung by James Jung
May 3, 2021
in K-Startup Grand Challenge
1
Reulaxis SAS

Regulaxis SAS is engaged in the development of innovative synthetic molecules.

0
SHARES
708
VIEWS
Share on FacebookShare on Twitter

The scope of regenerative treatments in the medical sector is growing with new methods and innovative solutions. French startup Regulaxis SAS is a biotech company that does research, development, and licensing of innovative synthetic molecules for human therapies.

The startup has gained much recognition for its pathbreaking new treatment for osteoarthritis by regenerating knee cartilage. Regulaxis SAS was one of the top companies at the K-Startup Grand Challenge (KSGC) 2020, South Korea’s biggest global accelerator program.

Specialized in the regulation of cell proliferation and cell differentiation

Regulaxis SAS is specialized in the regulation of cell proliferation and cell differentiation. The potential therapeutic applications covered by the patents it owns are extensive, especially in joint, bone, or nerve cell regeneration. It also helps in cancer and related metabolic diseases like diabetes, obesity. Regulaxix SAS’s mission is to grant licenses of innovative molecules in a pharmaceutical company after completing phase II clinical proof of concept.

The company leads its research and development on its premises at BIOCITECH, the technology park of life science, Paris North area, particularly regarding biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its molecules alone or establishes targeted collaborations with academic researchers or partnerships with companies interested in developing its therapeutic molecules.

Regulaxis’s unique antagonistic hormone combination promotes cell/tissue self-regulation and achieves the right balance between proliferation and differentiation depending on the target. Its product REG-O3 is focused on a mechanism of action that limits/stops the osteoarthritis damages at 3 targeted levels:

– Proliferation (Increase proliferation of progenitor cells/chondrocytes)

– Differentiation (Regeneration of mature chondrocytes pool)

– Anti-inflammatory

REG-O3 is a fully chemically synthesized peptide (liposomal formulation) to be injected into the knee synovial cavity.

Reg-O3 targeted market segment is the elderly population but also athletes and obese persons to slow down or even stop disease progression by proposing a disruptive treatment (curative and symptomatic action) using a painless local administration mode at a competitive price.

The K-Startup Grand Challenge experience 

Regulaxis SAS was founded by Claude Carelli, to develop innovative therapies for human clinics based on new synthetic peptides regulating cell growth and differentiation by modulating the activity of the growth factor (IGF- 1). The company’s inception was in September 2013 with funds from private investors. The startup has a 20-year research spin-off team from a French state-run research institute with four fully-owned patents.

The Europe-based startup had participated in K-Startup Grand Challenge (KSGC) 2020 program, the leading startup inbound program organized and financed by the Korean government. It is an all-expenses-paid 3.5-month program where startups get to reach out to potential investors, network and expand business in South Korea and the Asian market.

Regulaxis SAS was selected to be part of the program in 2020 out of 2,648 companies that had applied, and despite COVID-19 restrictions, the company got to spend considerable time in Korea. The startup was in the top-five league at the KSGC 2020 program winning fourth prize worth $20,000.

Elated with his company’s performance at the event, Raffaello Paolini, R&D Project Manager – East Asian operations development, said, “KSGC was a huge opportunity to leverage Covid slowdown in EU and in the US by accelerating our existing business plan for South Korea thanks to extended support in affiliate creation and training in Korean company rules and fiscal system.” Talking about the Regulaxis SAS team’s experience in South Korea and at KSGC, Paolini said, “The excitement of being incubated inside a super-active startup ecosystem at Pangyo campus with VISA support and proper mentoring was a great experience.”

The application and promotion of the K-Startup Grand Challenge 2021 have started with the last date for submitting applications being June 15th, 2021.

Read more about K-Startup Grand Challenge, 

  • K-Startup Grand Challenge: The gateway to South Korea for international startups
  • K-Startup Grand Challenge 2020 gets 33% more startup applicants than in 2019
  • K-Startup Grand Challenge – Matei Psatta: The Romanian startup founder, who is learning Korea’s ‘nunchi’ way of business
  • K-Startup Grand Challenge: Jordan Monnet: Matching investors with startups through NR2 platform
What’s your thoughts?
+1
0
Upvote
+1
0
Clap
+1
0
Clap
+1
0
On fire
+1
0
Meh
+1
0
Clap
+1
0
Tags: BiotechFrench startupK-Startup Grand Challenge 2020Regenerative therapyRegulaxis SAS
Previous Post

Malaysian startup Vechnology makes vending machines that use the e-wallet

Next Post

South Korea’s government aims to attract global startups with its residency and acceleration program

Next Post
K-Startup Grand challenge 2020

South Korea’s government aims to attract global startups with its residency and acceleration program

0 0 votes
Article Rating
Subscribe
Login
Notify of
Please login to comment
1 Comment
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
No Result
View All Result

Follow Us

FREE NEWSLETTER

Ecosystem Partners




PRODUCTS

Most Popular

  • 10 K-Dramas to watch for some ‘money matters’

    0 shares
    Share 0 Tweet 0
  • Korean startups fall short on global readiness, finds Open Innovation Trend survey

    0 shares
    Share 0 Tweet 0
  • UNDP-Citi Foundation’s impact startup acceleration programme ‘Citypreneurs 2023’ to promote innovative solutions for urban sustainability

    0 shares
    Share 0 Tweet 0
  • Top Korean Dating apps that can help you make new connections in South Korea

    1 shares
    Share 0 Tweet 0
  • Three Restaurant Apps to try out for a fine dining experience in South Korea  

    9 shares
    Share 9 Tweet 0
  • Fabless semiconductor startup Fadu raises pre-IPO funding, becomes this year’s first Korean unicorn

    0 shares
    Share 0 Tweet 0
  • Quantit secures  30 billion won Series A investment from Smilegate Holdings for AI-based FinTech Asset Management Services

    0 shares
    Share 0 Tweet 0
  • Korean startup launching a nose-print identification for dogs, an alternate to the microchip embedding process

    0 shares
    Share 0 Tweet 0
  • Korean government pledges to nurture K-Space startups with 50 billion won ‘space fund’

    0 shares
    Share 0 Tweet 0
  • Digital Healthcare startup CenacleSoft secures investment from Naver Cloud for its EMR platform

    0 shares
    Share 0 Tweet 0
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Copyright © 2023 KoreaTechDesk | About Us | Sponsorships| Terms of Use |Privacy Policy |Cookie Policy Contact: [email protected] DMCA.com Protection Status

No Result
View All Result
  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • FinTech
    • Gadgets & Electronics
    • Health & Bio
    • IoT
    • Marketplaces & E-commerce
    • Robotics
    • Transportation & Logistics
    • Investments
    • Ecosystem & Lists
  • Interviews
  • Events
    • ComeUp
    • NextRise
  • Governments
    • KISA
    • KISED
    • KOCCA
    • KTO
    • KOTRA
    • MSS
    • NIPA
    • SBA
    • SFL
  • Programs
    • LAUNCHPAD
    • COMEUP STARS 120
    • K-Startup Grand Challenge
    • TIPS X beSUCCESS Global Project
    • SFL Global Program
    • KTO Global Showcase
  • Investment Opportunities
    • Launchpad France Demoday
    • TIPS Global Demoday
    • Launchpad USA Demoday
    • Launchpad Indonesia Demoday
  • Submit an Article
  • Forums
  • register
  • login

Copyright © 2023 KoreaTechDesk | About Us | Sponsorships| Terms of Use |Privacy Policy |Cookie Policy Contact: [email protected] DMCA.com Protection Status

wpDiscuz
1
0
Would love your thoughts, please comment.x
()
x
| Reply

We hope you enjoy our content, May you please give us Feedback regarding our website!

Single Post Feedback

dgdfgfdgdf

What you think about Koreatechdesk, Share your idea with us!

feedback popup

Invitation submission has been closed

Insert/edit link

Enter the destination URL

Or link to existing content

    No search term specified. Showing recent items. Search or use up and down arrow keys to select an item.